Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2584
Source ID: NCT03938740
Associated Drug: Hdv-Insulin Lispro And Insulin Degludec (-40%)
Title: Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 1
Interventions: DRUG: HDV-Insulin Lispro and Insulin Degludec (-40%)|DRUG: HDV-Insulin Lispro and Insulin Degludec (-10%)
Outcome Measures: Primary: Basal, bolus and total insulin doses (UOM=units) during the last 2 weeks of the treatment period, Basal, bolus and total insulin doses (UOM=units) during the last 2 weeks of the treatment period, 24 weeks|Basal/bolus ratios during the last 2 weeks of the treatment period, Basal/bolus ratios during the last 2 weeks of the treatment period, 24 weeks |
Sponsor/Collaborators: Sponsor: Diasome Pharmaceuticals
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 61
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2019-03-18
Completion Date: 2020-03-18
Results First Posted:
Last Update Posted: 2020-04-02
Locations: Mills-Peninsula Medical Center, Diabetes Research Institute, San Mateo, California, 94401, United States|Barbara Davis Center for Diabetes, Aurora, Colorado, 80045, United States|Atlanta Diabetes Associates, Atlanta, Georgia, 30318, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, 30076, United States|Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina, 28557, United States|Texas Diabetes & Endocrinology, PA, Austin, Texas, 78749, United States|Texas Diabetes & Endocrinology, PA, Round Rock, Texas, 78681, United States
URL: https://clinicaltrials.gov/show/NCT03938740

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress